Evidence map›Paper›PMID 33134388›Full record

ArticleBioMed research international2020

Network Pharmacology-Based Strategy Reveals the Effects of

Shiying Zhang, Zhiying Yuan, Huaying Wu, Weiqing Li, Liang Li, Huiyong Huang

Open access · hybridAbstract read
In one paragraph

Article in BioMed research international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Annals of translational medicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Shiying ZhangHunan University of Chinese Medicine, Changsha, China.ORCID https://orcid.org/0000-0003-0984-0260
Zhiying YuanHunan University of Chinese Medicine, Changsha, China.
Huaying WuHunan University of Chinese Medicine, Changsha, China.
Weiqing LiDepartment of Traditional Chinese Medicine, Shenzhen Luohu People's Hospital, Shenzhen, China.ORCID https://orcid.org/0000-0002-4623-1854
Liang LiHunan University of Chinese Medicine, Changsha, China.ORCID https://orcid.org/0000-0001-9994-4690
Huiyong HuangHunan University of Chinese Medicine, Changsha, China.ORCID https://orcid.org/0000-0001-7803-3425
Hunan University of Traditional Chinese Medicine · CNShenzhen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo explore the effects of the

methodsTraditional Chinese Medicine (TCM)@Taiwan, TCM Systems Pharmacology Database and Analysis Platform (TCMSP), TCM Integrated Database (TCMID), and High-Performance Liquid Chromatography (HPLC) technology were used to obtain and screen HDC's active components, and the PharmMapper database was used to predict HDC human target protein targets. The DCM genes were collected from the GeneCards and OMIM databases, and the network was constructed and analyzed by Cytoscape 3.7.1 and the Database for Annotation, Visualization, and Integrated Discovery (DAVID). Finally, HDC was used to intervene in diabetic cardiomyopathy (DCM) model rats, and important biological processes and signaling pathways were verified using techniques such as immunohistochemistry.

resultsA total of 176 of HDC's active components and 442 potential targets were obtained. The results of network analysis show that HDC can regulate DCM-related biological processes (such as negative regulation of the apoptotic process, response to hypoxia, the steroid hormone-mediated signaling pathway, cellular iron ion homeostasis, and positive regulation of phosphatidylinositol 3-kinase signaling) and signaling pathways (such as the HIF-1 signaling pathway, the estrogen signaling pathway, insulin resistance, the PPAR signaling pathway, the VEGF signaling pathway, and the PI3K-Akt signaling pathway). Animal experiments show that HDC can reduce fasting plasma glucose (FPG), HbA1c, and malondialdehyde (MDA) and increase superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) (

conclusionIt was initially revealed that HDC improves DCM through its antiapoptotic and anti-inflammatory effects. HDC may play a therapeutic role by improving cardiomyocyte apoptosis in DCM rats.

Indexed as

AnimalsAntioxidantsApoptosisAstragalus propinquusBlood GlucoseCardiotonic AgentsDiabetic CardiomyopathiesDietary SugarsDiet, High-FatDrugs, Chinese HerbalGene Expression RegulationGlutathione PeroxidaseGlycated HemoglobinHypoxia-Inducible Factor 1, alpha SubunitMaleMalondialdehydeAntioxidantsBlood GlucoseCardiotonic Agentsdan-shen root extractDietary SugarsDrugs, Chinese HerbalGlutathione PeroxidaseGlycated HemoglobinHif1a protein, ratHuang QiHypoxia-Inducible Factor 1, alpha SubunitMalondialdehydePeroxisome Proliferator-Activated ReceptorsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSuperoxide DismutaseVascular Endothelial Growth Factor Avascular endothelial growth factor A, rat

Identifiers

PMID33134388
PMCPMC7591987
OpenAlexW3093551564

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.